However, gastrointestinal side effects were common and led to some treatment discontinuations, particularly at higher doses
5 (The lead authorship of this meta-analysis has industry ties to a myo-inositol manufacturer, and the German cohort cited below was led by an investigator at a myo-inositol distributor
Clinical references to muscle loss during GLP-1 treatment are based on published semaglutide and tirzepatide trial data
At Freeze Wellness, we find that both products work very well, but Tirzepatide seems to be more favorable for weight loss due to its dual action of having both GLP-1 and GIP actions
Choosing between tirzepatide and semaglutide depends on several factors, including weight loss goals, medical history, tolerance for side effects, and access to care
Understanding which factors elevate your baseline risk can help you and your healthcare provider make informed decisions about monitoring and prevention